{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T22:39:00Z","timestamp":1778884740545,"version":"3.51.4"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2019,7,15]],"date-time":"2019-07-15T00:00:00Z","timestamp":1563148800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,7,15]],"date-time":"2019-07-15T00:00:00Z","timestamp":1563148800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1038\/s41571-019-0255-8","type":"journal-article","created":{"date-parts":[[2019,7,15]],"date-time":"2019-07-15T17:05:02Z","timestamp":1563210302000},"page":"599-600","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Immune-checkpoint inhibition as first-line therapy for Hodgkin lymphoma"],"prefix":"10.1038","volume":"16","author":[{"given":"Alvaro J.","family":"Alencar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig H.","family":"Moskowitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,7,15]]},"reference":[{"key":"255_CR1","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1056\/NEJMoa1510093","volume":"374","author":"P Johnson","year":"2016","unstructured":"Johnson, P. et al. Adapted treatment guided by interim PET-CT scan in advanced Hodgkin\u2019s lymphoma. N. Engl. J. Med. 374, 2419\u20132429 (2016).","journal-title":"N. Engl. J. Med."},{"key":"255_CR2","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/S1470-2045(13)70341-3","volume":"14","author":"N Skoetz","year":"2013","unstructured":"Skoetz, N. et al. Effect of initial treatment strategy on survival of patients with advanced-stage Hodgkin\u2019s lymphoma: a systematic review and network meta-analysis. Lancet Oncol. 14, 943\u2013952 (2013).","journal-title":"Lancet Oncol."},{"key":"255_CR3","doi-asserted-by":"publisher","first-page":"2790","DOI":"10.1016\/S0140-6736(17)32134-7","volume":"390","author":"P Borchmann","year":"2018","unstructured":"Borchmann, P. et al. PET-guided treatment in patients with advanced-stage Hodgkin\u2019s lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group. Lancet 390, 2790\u20132802 (2018).","journal-title":"Lancet"},{"key":"255_CR4","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/S1470-2045(18)30784-8","volume":"20","author":"RO Casasnovas","year":"2019","unstructured":"Casasnovas, R. O. et al. PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma: a randomised, multicentre, non-inferiority, phase 3 study. Lancet Oncol. 20, 202\u2013215 (2019). (AHL2011).","journal-title":"Lancet Oncol."},{"key":"255_CR5","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1056\/NEJMoa1100340","volume":"365","author":"S Viviani","year":"2011","unstructured":"Viviani, S. et al. ABVD versus BEACOPP for Hodgkin\u2019s lymphoma when high-dose salvage is planned. N. Engl. J. Med. 365, 203\u2013212 (2011).","journal-title":"N. Engl. J. Med."},{"key":"255_CR6","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1056\/NEJMoa1708984","volume":"378","author":"JM Connors","year":"2018","unstructured":"Connors, J. M. et al. Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin\u2019s lymphoma. N. Engl. J. Med. 378, 331\u2013344 (2018).","journal-title":"N. Engl. J. Med."},{"key":"255_CR7","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","volume":"35","author":"R Chen","year":"2017","unstructured":"Chen, R. et al. Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma. J. Clin. Oncol. 35, 2125\u20132132 (2017).","journal-title":"J. Clin. Oncol."},{"key":"255_CR8","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1411087","volume":"372","author":"SM Ansell","year":"2015","unstructured":"Ansell, S. M. et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma. N. Engl. J. Med. 372, 311\u2013319 (2015).","journal-title":"N. Engl. J. Med."},{"key":"255_CR9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00315","author":"R Ramchandren","year":"2019","unstructured":"Ramchandren, R. et al. Nivolumab for newly diagnosed advanced-stage classic Hodgkin lymphoma: safety and efficacy in the phase II CheckMate 205 Study. J. Clin Oncol. JCO1900315. \n                    https:\/\/doi.org\/10.1200\/JCO.19.00315\n                    \n                   (2019).","journal-title":"J. Clin Oncol. JCO1900315"},{"key":"255_CR10","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1002\/hon.104_2629","volume":"37","author":"S Ansell","year":"2019","unstructured":"Ansell, S. et al. Nivolumab plus doxorubicin, vinblastine and dacarbazine for newly diagnosed advanced-stage classical Hodgkin lymphoma: Checkmate 205 Cohort D 2-year follow-up. Hematol. Oncol. 37, 146\u2013147 (2019).","journal-title":"Hematol. Oncol."}],"container-title":["Nature Reviews Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41571-019-0255-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41571-019-0255-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41571-019-0255-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:42:55Z","timestamp":1684618975000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41571-019-0255-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,15]]},"references-count":10,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["255"],"URL":"https:\/\/doi.org\/10.1038\/s41571-019-0255-8","relation":{},"ISSN":["1759-4774","1759-4782"],"issn-type":[{"value":"1759-4774","type":"print"},{"value":"1759-4782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,15]]},"assertion":[{"value":"15 July 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}